Hormonal
GLP-1 receptor agonists (GLP1RAs) such as semaglutide and liraglutide induce significant weight loss (5-15%) and improve metabolic markers by delaying gastric emptying, suppressing appetite via central nervous system signaling, and enhancing glucose-dependent insulin secretion.
GLP-1 medications like semaglutide and liraglutide are highly effective for weight loss (5-22%) and metabolic health. They work by slowing digestion and signaling fullness to the brain. Start with the lowest dose to minimize nausea, which usually improves over time. Combine with a calorie-controlled diet and exercise for best results. Oral versions exist but may have different absorption requirements.
GLP1RAs are known to directly interact with GLP-1 receptors in the circumventricular organs of the hypothalamus, the hind-brain and certain regions of the brain adjacent to ventricles that are considered to promote satiety and weight loss... Liraglutide delays the emptying of the stomach, reduces appetite, inhibits glucagon secretion and enhances insulin secretion in a glucose-dependent manner.
Why this rating
The paper cites multiple randomized controlled trials and FDA approvals, though it is a review article summarizing existing data rather than primary trial data itself.
Source
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Saqer S. Alotaibi et al. · Experimental and Therapeutic Medicine · 2025
DOI 10.3892/etm.2025.12912
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →